ReviewFrontiers in oncology2014
Evaluating biomarkers in melanoma.
Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Review
- Advancing precision immuno-oncology in melanoma: the synergistic convergence of personalized neoantigen vaccines and multi-omics biomarker profiling.Frontiers in immunology · 2026Review
- Paradigm of biomarkers in metastatic melanoma (Review).Oncology letters · 2025Review
- Liquid Biopsy for Cutaneous Melanoma: Opportunities and Challenges in Detecting and Characterizing Circulating Tumor Cells.Journal of dermato-oncology · 2025Article
- Combining Biomarkers for the Diagnosis of Metastatic Melanoma.Journal of clinical medicine · 2023Article
- Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers.Journal of translational medicine · 2022Article
- The Interplay between Tumour Microenvironment Components in Malignant Melanoma.Medicina (Kaunas, Lithuania) · 2022Review
- Mapping the Melanoma Plasma Proteome (MPP) Using Single-Shot Proteomics Interfaced with the WiMT Database.Cancers · 2021Article
- Evaluation of 2-methoxyestradiol serum levels as a potential prognostic marker in malignant melanoma.Molecular and clinical oncology · 2021Article
- The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis.Translational oncology · 2021Review
- MicroRNA-27b inhibits the development of melanoma by targeting MYC.Oncology letters · 2021Article
- Silencing Osteopontin Expression Inhibits Proliferation, Invasion and Induce Altered Protein Expression in Melanoma Cells.Pathology oncology research : POR · 2021Article
- RAGE Signaling in Melanoma Tumors.International journal of molecular sciences · 2020Review
- Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study.Molecular oncology · 2020Article
- Article
- Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.Cancer immunology, immunotherapy : CII · 2020Article
- The miRNAs Role in Melanoma and in Its Resistance to Therapy.International journal of molecular sciences · 2020Review
- Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study.Oncology reports · 2019Article
- A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma.Clinical proteomics · 2019Article
- BRAF inhibitors: resistance and the promise of combination treatments for melanoma.Oncotarget · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The incidence of cutaneous melanoma has more than doubled over the last decades making it one of the fastest rising cancers worldwide. Improved awareness and early detection of malignant moles now permit earlier diagnosis aiming to decrease the likelihood of recurrence. However, it is difficult to identify those patients initially diagnosed with localized melanoma who subsequently develop metastatic disease. For this group, prognosis remains poor and clinical outcomes are variable and challenging to predict. Considerable efforts have focused on the search for novel prognostic tools, with numerous markers evaluated in the circulation and in tumor lesions. The most reliable predictors of patient outcome are the clinical and histological features of the primary tumor such as Breslow thickness, ulceration status, and mitotic rate. Elevated serum levels of the enzyme lactate dehydrogenase, likely to indicate active metastatic disease, are also routinely used to monitor patients. The emergence of novel immune and checkpoint antibody treatments for melanoma and increasing appreciation of key roles of the immune system in promoting or halting cancer progression have focused attention to immunological biomarkers. Validation of the most promising of these may have clinical applications in assisting prognosis, assessing endpoints in therapy, and monitoring responses during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.